肺炎链球菌表面蛋白A的研究进展  

Progress in research on pneumococcal surface protein A

作　　者：钱婧[1] 曹玲[1] QIAN Jing;CAO Ling(Children＇s Hospital, Capital Institute of Paediatrics, Beijing 100020, China)

机构地区：[1]首都儿科研究所附属儿童医院,北京100020

出　　处：《中国生物制品学杂志》2018年第4期441-444,共4页Chinese Journal of Biologicals

摘　　要：肺炎链球菌(Streptococcus pneumonia,Sp)是儿童社区获得性感染的主要病原菌。目前使用较多的7价结合疫苗及23价肺炎链球菌多糖疫苗在长期使用后会出现血清型替换,这可能会使接种疫苗的受益程度下降。寻找新的候选疫苗是有效预防Sp疾病的重要途径,蛋白质疫苗因此备受关注。本文就近年来研究较多的下一代Sp疫苗的重要的候选蛋白质抗原,肺炎链球菌表面蛋白A(pneumococcal surface protein A,PspA)的研究进展作一简要综述。Streptococcus pneumonia（Sp）is the main pathogen of community-acquired infection in children.At present,the long-term use of heptavalent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine may induce serotype substitution,which may weaken the benefits of vaccination.Looking for a new candidate vaccine is an effective way to prevent the diseases caused by Sp.This paper reviews the progress in research on pneumococcal surface protein A（PspA）,the most important candidate antigen for the next generation of Sp vaccine.

关 键 词：肺炎链球菌表面蛋白A 蛋白质疫苗 儿童 

分 类 号：R378.14[医药卫生—病原生物学]